Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

GRTX earnings analysis

Filed May 14, 2026 · Our reading of the company's report

The latest report

Galera Therapeutics, Inc. has reported its financial results for Q1 2026, marking a slight improvement with a diluted EPS of -$0.08 compared to -$0.33 in Q4 2023. However, the company continues to face challenges with…

Read full summary

Galera Therapeutics, Inc. has reported its financial results for Q1 2026, marking a slight improvement with a diluted EPS of -$0.08 compared to -$0.33 in Q4 2023. However, the company continues to face challenges with no revenue reported and increasing cash burn, leading to concerns about its liquidity position entering the second quarter of 2027.

Read the original on SEC.gov

Reported figures

Earnings per share
$-0.08

What stood out

  • Improved EPS

    The diluted EPS improved to -$0.08 from -$0.33 in Q4 2023.

  • Decreased Operating Cash Burn

    Net cash used in operating activities decreased to $875,000 from $2.2 million in Q1 2025.

  • Reduction in R&D Expenses

    Research and development expenses dropped to $15,000 from $93,000 in Q1 2025.

  • Sufficient Cash for Near Term

    As of March 31, 2026, the company had $5.5 million in cash which is expected to fund operations into Q1 2027.

  • Change in Focus to New Pipeline

    The company has shifted its focus to the development of a pan-NOS inhibitor following the sale of its previous assets.

  • Significant PIPE Financing

    Galera has plans for a $350 million PIPE financing contingent on the completion of the Obsidian Merger.

What to watch

  • No Revenue Generated

    Galera reported no revenue, remaining dependent on capital raises to fund operations.

  • Substantial Doubt About Continuity

    There is significant concern about the company's ability to continue as a going concern beyond Q1 2027.

  • Obsidian Merger Risks

    Completion of the Obsidian Merger is uncertain, which could necessitate alternative strategies, potentially harming operations.

Management's outlook

Outlook deferred to earnings press release / call.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.